Australia's most trusted
source of pharma news
Wednesday, 27 May 2026
Posted 27 May 2026 AM
The TGA has hinted Novartis’ Tabrecta, GSK’s Exdensur, Specialised Therapeutics’ Zynyz, and Innocare Pharma’s Hibruka, could all be on the cusp of approval after announcing the Delegate’s final decision to add their active ingredients to the Poisons Standard.
These four drugs are among 12 New Chemical Entities (NCEs) to be added to the Poisons Standard that will come into effect on 1 June 2026, with the remaining NCEs listed already registered on the ARTG.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.